Anbio Biotechnology (NNNN) Common Equity (2023 - 2025)

Anbio Biotechnology has reported Common Equity for 3 years, with the latest figure at $30.2 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 75.41% year-over-year to $30.2 million; the trailing twelve-month figure through Dec 2025 stood at $30.2 million (up 75.41% YoY), and the FY2025 full-year result was $30.2 million, up 75.41% from the prior year.
• Common Equity for Q4 2025 stood at $30.2 million, up from $17.2 million in the prior quarter.
• The five-year high for Common Equity was $30.2 million in Q4 2025, with the low at $14.8 million in Q4 2023.
• Average Common Equity over 3 years is $20.7 million, with a median of $17.2 million recorded in 2024.
• Year-over-year, Common Equity rose 16.01% in 2024 and surged 75.41% in 2025.
• Tracing NNNN's Common Equity over 3 years: stood at $14.8 million in 2023, then climbed by 16.01% to $17.2 million in 2024, then surged by 75.41% to $30.2 million in 2025.
• The last three Common Equity figures came in at $30.2 million (Q4 2025), $17.2 million (Q4 2024), and $14.8 million (Q4 2023), per Business Quant data.

Peer Comparison